RCT | Effects of Docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation

Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation – Journal of Clinical Oncology (link to abstract – $ for full-text)

Editorial: Good Radiosensitizer Hunting – Journal of Clinical Oncology

Commentaries:

Docetaxel Added to Radiation Provides DFS, OS Benefit in Cisplatin-Ineligible HNSCC – OncLive

Docetaxel as a Radiosensitizer in Cisplatin-Ineligible Patients With Locally Advanced Head and Neck Cancer – The ASCO Post